FATE is an interesting company, just developing. There are about 480 thousand in cash, an annual loss of 173 thousand, Has 8 studies in 1 phase. Probably, it will “accumulate” one more year before significant phase studies (3), which corresponds to the negative scenario. And 2 in partnership with Janssen and Ono Pharma.
Curious FT596 with rituximab and FT538 with daratumumab, monoclonal antibodies that have been shown to be effective in autoimmune diseases with expiring patents
There is a chance for a rebound from the TA side, we stand at it200, there are divergence boundaries and small ones. It is necessary to wait for the rebound, since there is a possibility of disappearance up to 30.
It can, of course, always abruptly and unexpectedly upward without stopping, these are still scenarios.
Curious FT596 with rituximab and FT538 with daratumumab, monoclonal antibodies that have been shown to be effective in autoimmune diseases with expiring patents
There is a chance for a rebound from the TA side, we stand at it200, there are divergence boundaries and small ones. It is necessary to wait for the rebound, since there is a possibility of disappearance up to 30.
It can, of course, always abruptly and unexpectedly upward without stopping, these are still scenarios.